THU0543 A RETROSPECTIVE OVERVIEW OF THE TREATMENT MODALITY, OUTCOME AND RELAPSE RISK OF IGG4 RELATED DISEASE IN HONG KONG: A DATASET OF 108 PATIENTS FROM FOUR REGIONAL HOSPITALS
Background: Currently most consensus suggests treating IgG4 related disease (IgG4RD) with prednisolone 0.6mg/kg/day tapering over 6 months while some experts prefer continuation of steroid up to 3 years (1-3). Objectives: In this retrospective study, the treatment modality, response and relapse risk of IgG4RD patients over the past ten years from four regional hospitals in Hong Kong were analyzed. Methods: Four regional hospitals participated with study period from 1/1/2006 to 30/6/2016. Patients were diagnosed IgG4RD according to the Japanese Comprehensive Diagnostic Criteria for IgG4RD. Treatment response at 6 months was recorded as complete, partial or non-remission based on the patient's and physician's perspective. Relapse was defined as disease progression either clinically or radiologically.
Statistical analysis:
The association between treatment response and steroid dosage was analyzed by multivariate logistic regression. Risk factors for relapse were analyzed by multivariate cox regression and the hazard ratio was reported. Results: 37 cases had surgical excision and disease recurred in 5 cases (relapse rate =13.5%). 87 patients (81%) received steroid treatment. The mean starting prednisolone was 33.5mg daily, with a mean duration of 95.2 weeks. At 6 months, 5 patients (6%) had no response, 34 patients (41%) had partial remission and 44 patients (53%) had complete remission. 29 patients also received other immunosuppressants, including azathioprine (n=25), mycophenolate mofetil (MMF) (n=6), cyclosporine A (n=4), mercaptopurine (n=2) and rituximab (n=1). The overall response rate for azathioprine and MMF was 64% and 67% respectively. In the final multiple logistic regression, an initial prednisolone 30mg daily or above was associated with a higher complete remission at 6 months (OR=3.4, p=0.079) and the effect was more seen in patients with salivary and orbital involvement (OR=6.8, p=0.10) 18 patients relapsed after steroid was stopped and 6 patients relapsed while on prednisolone 2.5-7.5mg daily. The one year, two year and three year relapse rate were 13.3%, 24.1% and 26.5% respectively. In the final multivariate cox regression, the presence of maintenance steroid was associated with a lower relapse risk (Hazard ratio=0.121, p=0.000) while serum IgG4 level above twice upper limit of normal (Hazard ratio=5.283, p=0.029) and hepatobiliary involvement (Hazard ratio=2.164, p=0.095) were associated with a higher relapse risk. Conclusions: Most patients (94%) had good response to steroid. Patients with hepatobiliary involvement and serum IgG4 level above twice upper limit of normal were at higher relapse risk and a low dose, maintenance prednisolone for longer period is recommended. Background: Familial Mediterranean fever (FMF) is an autosomal recessive inherited disease with recurrent fever and inflammatory episodes of serous membranes. The MEFV (Mediterranean fever) gene in the short arm of chromosome 16 is affected in the FMF. This gene encodes for a protein called 'Pyrin'. The erroneously synthesized Pyrin protein due to MEFV mutations is unable to control the post inflammatory process. Although there have been many efforts to find out genotype-phenotype association in FMF, no clear relationship has been clarified. Objectives: In this study, the relationship between FMF clinical symptoms and MEFV gene mutations and polymorphism was investigated. Methods: Total of 158 patients with FMF was included to the study that was conducted in a tertiary rheumatology outpatient clinic. The demographic and clinical features, as well as MEFV gene mutations were recorded in a "Patient Assessment Form". The clinical status of the disease was evaluated with FMFseverity score-2 (F-SS-2). The associations between clinical features and genetic alterations were calculated with Pearson Chi-square test. Results: The mean age of patients was 24.3±5.1, mean delay in diagnosis was 5.6±6.3 years, and 155 of the patients (%98.1) were male. The percentage of patients stating they use colchicine regularly was 136 (86.1%), and mean dose was 1.4±0.3 mg/day. The most frequent mutation was M694V (76.6%), and R202Q, M680I and E148Q were found in a descending order (60.8%, 19.0% and 13.9%, respectively). The FMF severity score was found to be higher in patients carrying M694V mutation (p=0.01). In comparison with negative family history for FMF, M694V was more prevalent in patients with positive family history (82.0% vs 67.2%, p=0.035). Besides, M694V mutation found to be associated with arthritis (p=0.045). E148Q mutation was associated with the history of orchitis (p=0.029). The most significant relation between E148Q and clinical feature was family history of hemodialysis (p=0.005). The prevalence of non-periodic myalgia was %34.2, and this symptom was not present in patients carrying V726A mutation (p=0.005). M694V/R202Q was the most prevalent compound heterozygosis and found in 16 patients (10.1%). This mutation (M694V/R202Q) was associated with fewer frequencies of myalgia and peritonitis, and with good response to colchicine.
Conclusions:
The presence of R202Q polymorphism is associated with FMF, and should be considered in the routine genetic analysis of the disease. In our patients, its co-existence with M694V seems to be associated with good response to colchicine, and to alleviate the severity of the disease expression of M694V, which is known to be associated with severe course. Background: Multicentric Castleman's disease (MCD) is a disorder characterized by polyclonal proliferation of B lymphocytes that is frequently associated with autoimmune manifestations and connective tissue diseases. MCD presents high levels of IL-6 and systemic symptoms such as fever, arthralgia, hepatosplenomegaly and serositis, so it is recommended to include MCD in the differential diagnosis of adult-onset Still's disease (AOSD). However, there are no studies comparing both groups of patients. Objectives: To compare the clinical and laboratory features at onset between patients with MCD and AOSD seen in a Madrid tertiary care hospital. Methods: We performed a retrospective observational study in patients with diagnosis MCD and AOSD attended our center between January 1989 and December 2015. The variables included demographics, clinical manifestations, laboratory tests and Yamaguchi's criteria. Results: A total of 34 patients were included, 17 with MCD and 17 with AOSD. The comparison of the characteristics of both groups is presented in the table. There were no differences in age, uration of disease (MCD 158,6 days and AOSD 250,5 days, p=0,3919), diagnostic delay (MCD 18,4 and AOSD 52,2, p=0,2711), arthritis, myalagias, pleuritis or macrophagic activation syndrome, but persistent fever, rash, arthralgia, pharyngitis and pericarditis were significantly more frequent in ESA, whereas male gender, human immunodeficiency virus (HIV) and/or human herpes virus 8 (HHV8) infection, hepatosplenomegaly and lymphadenopathy were significantly higher in MCD. In the laboratory test results, leukocytosis and hypertransaminasemia were significantly higher in AOSD. 52.9% of patients with MCD met 5 or more Yamaguchi's criteria for AOSD. Background: Langerhans cell histiocytosis (LCH) is a rare condition, and mostly affects children. Bone is the most commonly involved organ, with bone lesions in 50% of patients. In a recent work, Aricò et al. described that the probability of survival in children suffering from a multisystemic LCH with risk organ involvement was reduced if patient did not have any bony lesion [1] . There is no such a study in adult patients. Objectives: The objective of the study was to know the bone impact on the prognosis of adult LCH. Methods: A retrospective monocentric study was performed using data from the patients hospitalized for a LCH at Centre Hospitalier Régional Universitaire de Lille, a university hospital between 2001 and 2015. All patients with LCH and at an age of 18 years or older were included. Patients were excluded if they did not receive any osteoarticular imaging (radiography, scintigraphy, PET, MRI). Results: Our study initially included 70 patients had LCH. After screening 54 patients met the inclusion criteria: 31 had bone localization (BLG) and 23 none (NBLG). The two groups showed differences. The lesion leading to the diagnosis was mostly osteoarticular (18 patients) in BLG and pulmonary (18 patients) in NBLG. The BLG presented more multisystemic form than the NBLG (20 vs 2, p<0.0001). Both groups were equivalent for comorbidities (p=0,206 for cancer and p=0,756 for cardiovascular disease), number of smokers and age at diagnosis (36.8+/-14.15 years vs 36.7+/-12.6 years, p=0.96 and 25 vs 22, p=0.06). Treatment was required for 14 patients in BLG and for 2 in NBLG. In BLG, 8 patients were treated medically, mostly by corticosteroid therapy and chemotherapy (7), one patient underwent radiotherapy. 6 patients were treated by surgery. In NBLG, 2 patients were treated by corticosteroid therapy. There was no surgery in NBLG (table 1) . 3 patients died in BLG, 2 directly related to LCH and one from postoperative infectious complications. One patient died in NBLG from hematologic pathology (chronic myelomonocytic leukemia). The time between diagnosis and death was one, six and 22 months in BLG, 36 months in NBLG. 7 patients presented relapses in BLG. 5 had been treated by medical treatment, one surgically and one had no previous treatment. Background: Mevalonate kinase deficiency (MKD) is a rare autosomal recessive autoinflammatory disease caused by mutations in MVK gene. MKD patients typically have an early onset of symptoms including recurrent episodes of high fever, abdominal pain, diarrhea and vomiting, arthralgia and lymphadenopathy (AIDAI criteria for HIDS). However not all patients have typical symptoms at the time of onset. MKD treatment remains an unsolved problem, since none of the modalities previously used for MKD treatment are fully effective in the disease control. Methods: We conducted a retrospective analysis of clinical features of twelve patients (6 females, 6 males) with genetically confirmed MKD. Nine patients received therapy with inhibitors of IL-1 (Anakinra and/or Canakinumab). One of the patients died from amyloidosis and macrophage activation syndrome (MAS) prior to treatment initiation, her diagnosis was verified post mortem. Results: Ten patients had manifested within the first 6 months of life, one -at the age of 1.5 years, one -at three years of age,. During the course of the disease all patients had periodic fever and peripheral lymphadenopathy (mainly cervical group), as well as abdominal pain, nausea/vomiting. Five patients had diarrhea, sometimes with blood, one patient suffered from severe constipation. Rash was seen in eight patients, myalgia, artralgia were observed only in six. Oral ulcers were noted in seven children. Three patients had neurological involvement, one patient had it as the main symptom. One patient had periorbital edema and hyperemia during attacks, which to our knowledge, have not been reported previously in MKD. One patient developed amyloidosis and MAS before IL1 inhibitor treatment initiation, which led to her death. In patients receiving anti-IL-1 therapy AIDAI index decreased from 58.3±11,2 before to 1,5±1,4 after 6 month of therapy (p=0.003). Conclusions: MKD symptoms can be variable and sometimes atypical, which requires physician's awareness. In our cohort of MKD patients anti IL-1 therapy was highly effective. Disclosure of Interest: None declared DOI: 10.1136/annrheumdis-2017-eular.2238 
